Study of efgartigimod for nerve damage in Sjogren's disease
Treatments studied
This trial tests a medication called efgartigimod that may help people with Sjogren's disease who have nerve damage causing numbness, tingling, or weakness. The drug works by blocking certain antibodies that are thought to attack the nerves. It aims to improve nerve symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have Sjogren's disease, confirmed by a blood test for anti-Ro/SS-A antibodies.
- Your nerve symptoms started within the last 5 years and have been getting worse in the past year.
- You must have at least mild nerve damage on a standard neurological exam.
- You do not have other rheumatic diseases like rheumatoid arthritis or lupus, and your fibromyalgia is well managed.
- You have not used steroids (by mouth, vein, or muscle) more than 3 times in the last year for other health issues like asthma or COPD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial looks at people with Sjögren who may have small-fiber nerve problems that can cause pain, temperature-related nerve symptoms, or body-function nerve issues. It aims to understand how these nerve problems affect quality of life and medical needs, and compare them with people without neuropathy.
This trial tests an experimental drug, IMVT-1402, in adults with primary Sjogren's disease who have moderate to severe symptoms. The goal is to see if it can reduce disease activity safely.
This study tests an investigational drug called ESG206, which targets a protein on immune cells, to see if it can safely reduce symptoms of primary Sjögren's syndrome. It is for people whose Sjögren's is not caused by another disease and who have active symptoms.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
Hear when a new Sjogrens Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.